Cybin Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Doug Drysdale

Amministratore delegato

CA$2.1m

Compenso totale

Percentuale dello stipendio del CEO	32.6%
Mandato del CEO	4yrs
Proprietà del CEO	0.02%
Durata media del management	4yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Doug Drysdale rispetto agli utili di Cybin?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-CA$124m
Jun 30 2024	n/a	n/a	-CA$78m
Mar 31 2024	CA$2m	CA$681k	-CA$78m
Dec 31 2023	n/a	n/a	-CA$70m
Sep 30 2023	n/a	n/a	-CA$51m
Jun 30 2023	n/a	n/a	-CA$49m
Mar 31 2023	CA$804k	CA$680k	-CA$47m
Dec 31 2022	n/a	n/a	-CA$52m
Sep 30 2022	n/a	n/a	-CA$58m
Jun 30 2022	n/a	n/a	-CA$66m
Mar 31 2022	CA$3m	CA$549k	-CA$68m
Dec 31 2021	n/a	n/a	-CA$63m
Sep 30 2021	n/a	n/a	-CA$58m
Jun 30 2021	n/a	n/a	-CA$43m
Mar 31 2021	CA$2m	CA$277k	-CA$32m

Compensazione vs Mercato: La retribuzione totale di Doug ($USD 1.50M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.46M ).

Compensazione vs guadagni: La retribuzione di Doug è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Doug Drysdale (54 yo)

4yrs

Mandato

CA$2,092,583

Compensazione

Mr. Douglas L. Drysdale, also known as Doug, is Chief Executive Officer at Cybin, Inc. since November 05, 2020. Mr. Drysdale serves as the Member of Board of Directors for SpineThera, Inc. from May 2022. H...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	4yrs	CA$3.36m	1.53% $ 3.2m
Douglas Drysdale	Chief Executive Officer	4yrs	CA$2.09m	0.020% $ 42.2k
Paul Glavine	Co-Founder	no data	CA$3.36m	1.47% $ 3.0m
Greg Cavers	Chief Financial Officer	4yrs	CA$880.42k	0.013% $ 26.7k
Aaron Bartlone	Chief Operating Officer	1.3yrs	CA$1.03m	0.12% $ 240.9k
George Tziras	Chief Business Officer & Director	1.1yrs	CA$310.55k	0.17% $ 346.2k
John Kanakis	Co-Founder	no data	CA$1.49m	Nessun dato
Alex Nivorozhkin	Chief Scientific Officer	3.9yrs	Nessun dato	0% $ 0
Lori Challenger	Chief Compliance	3.1yrs	Nessun dato	Nessun dato
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	4yrs	Nessun dato	0.052% $ 107.8k
Sara Somerset	Chief Communications Officers	no data	Nessun dato	Nessun dato
James Andrews	Chief Cultivation & Extraction Officer	no data	Nessun dato	Nessun dato

4.0yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di CYBN è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	4yrs	CA$3.36m	1.53% $ 3.2m
Paul Glavine	Co-Founder	4yrs	CA$3.36m	1.47% $ 3.0m
George Tziras	Chief Business Officer & Director	1.1yrs	CA$310.55k	0.17% $ 346.2k
Theresa Firestone	Lead Independent Director	3.3yrs	CA$304.80k	0.0052% $ 10.8k
Mark Lawson	Independent Director	4yrs	CA$291.56k	0.015% $ 30.7k
Grant Froese	Independent Director	4yrs	CA$289.80k	0.026% $ 53.5k
Eric Hoskins	Independent Director	4yrs	CA$289.80k	0.013% $ 26.7k

4.0yrs

Durata media

51yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CYBN sono considerati esperti (durata media dell'incarico 4 anni).

Cybin Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cybin Inc. Announces Executive Appointments

Insufficient new directors

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Recent updates

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

No longer forecast to breakeven

New minor risk - Share price stability

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought US$56k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022

Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain